Thursday, April 14, 2022 3:34:22 PM
1, Home infusions in the trial kept the trials going (because of covid) and will be very helpful in the future.
2, Much less infusion reaction is an important patient positive which alone will stimulate switching to PRX-102.
3, He appeared to be thrilled to have been part of an actual comparative study and potentially have a better treatment option, rather than telling patients US patients he has only one treatment option to provide.
4, In response to a question at the end, PRX-102 does not reverse the disease but PRX-102 better slows the decline vs Fabrazyme and improves the quality of life.
Other matters of importance:
1. It was the FDA that changed the study to non-inferiority from inferior because they officially approved Fabrazyme recently.
2, I though Dr. Warnick was very clean in saying that there is nothing being developed by others (such as gene therapy) that is anywhere near replacing ERTs as Fabry treatments. Looks like if approved by early next year PRX via Chiesi will have years to have Dror's predication of a potential $1 billion royalty stream a reality.
3. PLX has plenty of compacity now and in the future to meet demand.
4. PLX believes if approved it will include both the twice and once monthly treatments. There are now 150+ patients in the extension studies which include both twice and once a monthy treatments.
Conclusion: We just have to wait for the approval process to run its course. Hope this summation is helpful and will convert traders into long-term holders of PLX.
Recent PLX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 09:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 09:00:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 11:02:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 10:56:02 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/17/2024 09:05:17 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/17/2024 09:00:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 11:20:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 10:59:36 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/02/2024 11:36:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 11:56:21 AM
- Levicept Appoints Eliot Forster as CEO • GlobeNewswire Inc. • 11/30/2023 09:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 12:50:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 12:22:32 PM
- Upcoming Earnings Release Paired With Price Target Raise Sends Stock Soaring • AllPennyStocks.com • 10/31/2023 08:40:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/20/2023 10:50:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:50 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM